{"brief_title": "Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II", "brief_summary": "The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.", "condition": ["Pulmonary Hypertension"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["bosentan", "placebo"], "description": ["65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study", "placebo for 6 months followed by an open-label period"], "arm_group_label": ["1", "2"], "other_name": ["Tracleer"], "criteria": "Inclusion Criteria: - PAH NYHA Class II - Significant elevation of mean pulmonary arterial pressure - Significant elevation of pulmonary vascular resistance at rest - Limited 6-minute walk distance Exclusion Criteria: - PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt - Restrictive or obstructive lung disease - Significant vasoreactivity - Treatments for PAH (within 4 weeks of randomization)", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "early", "mesh_term": ["Hypertension", "Hypertension, Pulmonary", "Familial Primary Pulmonary Hypertension", "Bosentan"], "id": "NCT00091715"}